US launch of Visian TICL delayed

Article

Staar Surgical has revealed that its Visian toric implantable collamer lens (TICL) is unlikely to receive FDA approval in 2007.

Staar Surgical has revealed that its Visian toric implantable collamer lens (TICL) is unlikely to receive FDA approval in 2007.

The FDA has decided that, since the TICL is a first-of-its-kind device, it should be submitted to the Ophthalmic Devices Panel of the Center for Devices and Radiological Health for evaluation.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
Frank Kerkhoff, MD, PhD, and visual acuity charts following implantation with the Johnson and Johnson Tecnis Odyssey lens.

Q&A: Early research findings and clinical experiences with a new multifocal IOL

Frank Kerkhoff, MD, PhD ;Hattie Hayes
July 17th 2025
Article

Frank Kerkhoff, MD, shares his experiences with the Johnson & Johnson Tecnis Odyssey lens

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A row of beakers with yellow and orange fluid in a laboratory. Concept image for microbial lutein production, bioengineering, sustainable synthesis for cataract cornea age-related macular degeneration (AMD) and retinal disease. Image credit: bidala – stock.adobe.com

New microbial strain produces high yields of lutein for AMD, cataract prevention

Kassi Filkins
July 15th 2025
Article

Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Lynda Charters
July 13th 2025
Article
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Jordana Joy
July 12th 2025
Article

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Health Canada approves aflibercept biosimilar Aflivu

Health Canada approves aflibercept biosimilar Aflivu

Sydney M Crago
July 10th 2025
Article

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

© 2025 MJH Life Sciences

All rights reserved.